These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 29153631)

  • 21. Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: Pooled results from three Phase III studies.
    Moseley BD; Sperling MR; Asadi-Pooya AA; Diaz A; Elmouft S; Schiemann J; Whitesides J
    Epilepsy Res; 2016 Nov; 127():179-185. PubMed ID: 27608437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. No Abuse Potential of Silexan in Healthy Recreational Drug Users: A Randomized Controlled Trial.
    Seifritz E; Möller HJ; Volz HP; Müller WE; Hopyan T; Wacker A; Schläfke S; Kasper S
    Int J Neuropsychopharmacol; 2021 Mar; 24(3):171-180. PubMed ID: 33300578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo.
    Hindmarch I; Dawson J; Stanley N
    Sleep; 2005 Feb; 28(2):187-93. PubMed ID: 16171242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Absence of psychostimulant effects of a supratherapeutic dose of tianeptine: a placebo-controlled study versus methylphenidate in young healthy volunteers.
    Bernard K; Penelaud PF; Mocaër E; Donazzolo Y
    J Clin Psychopharmacol; 2011 Aug; 31(4):441-8. PubMed ID: 21694627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users.
    Koblan KS; Hopkins SC; Sarma K; Gallina N; Jin F; Levy-Cooperman N; Schoedel KA; Loebel A
    Drug Alcohol Depend; 2016 Feb; 159():26-34. PubMed ID: 26794682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health-related quality of life in double-blind Phase III studies of brivaracetam as adjunctive therapy of focal seizures: A pooled, post-hoc analysis.
    Brandt C; Borghs S; Elmoufti S; Mueller K; Townsend R; de la Loge C
    Epilepsy Behav; 2017 Apr; 69():80-85. PubMed ID: 28236727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conversion to brivaracetam monotherapy for the treatment of patients with focal seizures: Two double-blind, randomized, multicenter, historical control, Phase III studies.
    Arnold S; Badalamenti V; Diaz A; Gasalla T; McShea C; Whitesides J; Fakhoury T
    Epilepsy Res; 2018 Mar; 141():73-82. PubMed ID: 29486396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study.
    Stauffer J; Setnik B; Sokolowska M; Romach M; Johnson F; Sellers E
    Clin Drug Investig; 2009; 29(12):777-90. PubMed ID: 19888784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users.
    Smith MD; Webster LR; Lawler J; Lindhardt K; Dayno JM
    Pain Med; 2017 May; 18(5):898-907. PubMed ID: 27633773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans.
    Busto U; Kaplan HL; Zawertailo L; Sellers EM
    Clin Pharmacol Ther; 1994 Apr; 55(4):451-63. PubMed ID: 8162672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abuse liability and clinical pharmacokinetics of alprazolam in alcoholic men.
    Ciraulo DA; Barnhill JG; Greenblatt DJ; Shader RI; Ciraulo AM; Tarmey MF; Molloy MA; Foti ME
    J Clin Psychiatry; 1988 Sep; 49(9):333-7. PubMed ID: 3417618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users.
    Backonja M; Webster LR; Setnik B; Bass A; Sommerville KW; Matschke K; Malhotra BK; Wolfram G
    Am J Drug Alcohol Abuse; 2016 Sep; 42(5):539-549. PubMed ID: 27211522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of abuse liability of Tramadol among experienced drug users: Double-blind crossover randomized controlled trial.
    Das M; Jain R; Dhawan A; Kaur A
    J Opioid Manag; 2016; 12(6):421-430. PubMed ID: 28059434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users.
    Setnik B; Bramson C; Bass A; Levy-Cooperman N; Malhotra B; Matschke K; Sommerville KW; Wolfram G; Geoffroy P
    J Clin Pharmacol; 2015 Dec; 55(12):1351-61. PubMed ID: 26011742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men.
    Rolan P; Sargentini-Maier ML; Pigeolet E; Stockis A
    Br J Clin Pharmacol; 2008 Jul; 66(1):71-5. PubMed ID: 18341673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial.
    Kwan P; Trinka E; Van Paesschen W; Rektor I; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):38-46. PubMed ID: 24116853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Brivaracetam for add-on treatment in focal epilepsy].
    Strzelczyk A; Steinig I; Klein KM; Willems LM; Knake S; Rosenow F; Bauer S
    Nervenarzt; 2016 Oct; 87(10):1086-1093. PubMed ID: 27389600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.
    Ryvlin P; Werhahn KJ; Blaszczyk B; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):47-56. PubMed ID: 24256083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the subjective and reinforcing effects of diphenhydramine, levetiracetam, and valproic acid.
    Feltner DE; Haig G
    J Psychopharmacol; 2011 Jun; 25(6):763-73. PubMed ID: 20147572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy.
    Setnik B; McDonnell M; Mills C; Scart-Grès C; Robert P; Dayno JM; Schwartz JC
    Sleep; 2020 Apr; 43(4):. PubMed ID: 31626696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.